Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 20;15(1):20144.
doi: 10.1038/s41598-025-05088-9.

Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells

Affiliations

Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells

Hanan R H Mohamed et al. Sci Rep. .

Abstract

Pancreatic cancer is a hard-to-treat tumor with a poor prognosis. While traditional pancreatic cancer therapies can be effective, issues like cytotoxicity, low selectivity, and drug resistance still pose major challenges. Nanotechnology has shown promise in improving cancer diagnosis and treatment. Yttrium oxide nanoparticles (Y2O3-NPs), for example, have demonstrated potent selective cytotoxicity against triple negative breast cancer cells; but their effects on pancreatic cancer cells have not been explored. This study aimed to explore the impact of Y2O3-NPs on cell proliferation, DNA integrity, and oxidative stress in pancreatic cancer (PANC-1) and human skin fibroblast (HSF) cells. The cytotoxicity of Y2O3-NPs after 72 h were estimated using Sulforhodamine (SRB) cytotoxicity assay, while alkaline Comet assay was done to study genomic DNA integrity. Generation level of reactive oxygen species (ROS) and integrity of mitochondrial membrane potential were also analyzed. Apoptosis induction was investigated using Flow Cytometry and expression level of apoptotic (p53), anti-apoptotic (Bcl2) and mitochondrial (ND3) genes was measured using quantitative RTPCR. Our findings exhibited that Y2O3-NPs had strong selective cytotoxicity against PANC-1 cells with an IC50 value of 31.06 µg/ml, while having minimal effect on normal HSF cells (IC50 = 319.21 µg/ml). Treatment of PANC-1 cells with Y2O3-NPs at the IC50 concentration for 72 h significantly increased intracellular ROS levels and DNA damage, along with a notable reduction in mitochondrial membrane potential. Additionally, a significant rise in necrotic, early, and late apoptotic cells was observed, accompanied by downregulation of the anti-apoptotic Bcl2 gene and upregulation of the apoptotic p53 and mitochondrial ND3 genes. These findings highlight the selective toxicity of Y2O3-NPs towards cancerous PANC-1 cells, with minimal impact on normal cells. Y2O3-NPs appear to induce apoptosis in cancer cells by increasing ROS generation, damaging DNA, disrupting mitochondrial function, and triggering cell death. This study suggests that Y2O3-NPs may be a promising candidate for pancreatic cancer treatment. Further research is needed to fully explore their therapeutic potential.

Keywords: Apoptosis; Cytotoxicity; DNA damage; Mitochondrial integrity; Pancreatic cancer cancers; ROS; Y2O3-NPs.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Viability of pancreatic PANC-1 cancer cells after exposure to five concentrations of Y2O3-NPs for 72 h.
Fig. 2
Fig. 2
Viability of normal HSF cells after exposure to five concentrations of Y2O3-NPs for 72 h.
Fig. 3
Fig. 3
Level of ROS generation within untreated and treated PANC-1 cells with an IC50 concentration of Y2O3-NPs for 72 h.
Fig. 4
Fig. 4
Examples for the scored Comet nuclei with intact and various DNA damage in the untreated and treated PANC-1 cells with an IC50 concentration of Y2O3-NPs for 72 h.
Fig. 5
Fig. 5
Integrity of mitochondrial membrane potential in the untreated and treated PANC-1 cells with an IC50 concentration of Y2O3-NPs for 72 h.
Fig. 6
Fig. 6
Apoptosis induction in the untreated (control) and treated PANC-1 cells with an IC50 concentration of Y2O3-NPs for 72 h. Q2-1 denotes necrosis phase; Q2-2 denotes late apoptosis phase, Q2-3 denotes normal viable cells and Q2-4 denotes early apoptosis phase.

Similar articles

References

    1. Duan, H., Li, L. & He, S. Advances and prospects in the treatment of pancreatic cancer. Int. J. Nanomed.18, 3973–3988 (2013). - PMC - PubMed
    1. Schepis, T. et al. State-of-the-art and upcoming innovations in pancreatic cancer care: A step forward to precision medicine. Cancers (Basel)15(13), 3423 (2023). - PMC - PubMed
    1. Quiñonero, F. et al. The challenge of drug resistance in pancreatic ductal adenocarcinoma: A current overview. Cancer Biol Med16(4), 688–699 (2019). - PMC - PubMed
    1. Martín, A. M. et al. From first line to sequential treatment in the management of metastatic pancreatic cancer. J. Cancer9(11), 1978–1988 (2018). - PMC - PubMed
    1. Cho, I. R. et al. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World J. Gastrointest. Oncol.12(2), 182–194 (2020). - PMC - PubMed

MeSH terms